Company Overview
VISTAGEN THERAPEUTICS, INC.
VTGNRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
—M
2024 FY
Net Income
-51M
2024 FY
Shares Outstanding
31M
2024 FY
EPS
-1.67USD
2024 FY
Company Information
SIC Code
2834
CIK Code
1411685
Exchange
Nasdaq
Location
US